AgeX Therapeutics Inc (AGE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Michael D. West
Employees:
10
965 ATLANTIC AVENUE, SUITE 101, ALAMEDA, CA 94501
510-671-8370

AgeX Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity.

Data derived from most recent annual or quarterly report
Market Cap 25.807 Million Shares Outstanding37.951 Million Avg 30-day Volume 20.343 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.07
Price to Revenue941.6065 Debt to Equity-1.4806 EBITDA-3.479 Million
Price to Book Value0.0 Operating Margin-20488.8889 Enterprise Value66.527 Million
Current Ratio0.055 EPS Growth0 Quick Ratio0.011
1 Yr BETA -0.2403 52-week High/Low 1.0 / 0.37 Profit Margin-31002.7778
Operating Cash Flow Growth6.8277 Free Cash Flow to Firm (FCFF) TTM -22.825 Million Free Cash Flow to Equity (FCFE) TTM10.837 Million
Altman Z-Score-17.5825

Are you looking for this stock instead?

View SEC Filings from AGE instead.

View recent insider trading info

AgeX Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AGE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-08-21 by RENONDIN JEAN-CHRISTOPHE
  • 4: filed on 2023-05-18 by JUVENESCENCE LTD
  • 4: filed on 2023-03-22 by JUVENESCENCE LTD
  • 3: filed on 2023-03-22 by JUVENESCENCE US CORP.
  • 4: filed on 2023-02-17 by JUVENESCENCE LTD
  • 4: filed on 2023-02-08 by JUVENESCENCE LTD
  • 4: filed on 2022-12-19 by JUVENESCENCE LTD
  • 4: filed on 2022-10-27 by JUVENESCENCE LTD
  • 4: filed on 2022-09-13 by WEST MICHAEL D
  • 4: filed on 2022-08-24 by JUVENESCENCE LTD

    • Events (8k)

  • 8-K: filed on 2023-09-15:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-25:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-07:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RENONDIN JEAN-CHRISTOPHE

    • Director
    		 0 2023-08-09 1

    JUVENESCENCE LTD

    • Director
    • 10% Owner
    		 0 2023-04-25 6

    JUVENESCENCE US CORP.

    • Director
    • 10% Owner
    		 16,447,500 2023-03-14 1

    WEST MICHAEL D CHIEF EXECUTIVE OFFICER

    • Officer
    		 41,982 2023-03-11 2

    HACKETT JOANNE M.

    • Director
    		 65,000 2022-02-02 0

    BAILEY GREGORY

    • Director
    		 65,000 2021-06-21 0

    JENKINS ANNALISA

    • Director
    		 65,000 2021-06-21 0

    MAY MICHAEL H

    • Director
    		 100,000 2021-06-21 0

    STERNBERG HAL VICE PRESIDENT-RESEARCH

    • Officer
    		 5,000 2021-06-04 0

    SEGALL JUDITH DIRECTOR OF ADMIN & SECRETARY

    • Officer
    		 3,000 2021-06-04 0

    MALIK NAFEES NASEER CHIEF OPERATING OFFICER

    • Officer
    		 75,000 2021-06-04 0

    PARK ANDREA EUN JAE CHIEF FINANCIAL OFFICER

    • Officer
    		 75,000 2021-06-04 0

    BAGBY ROBERT L CEO & CH OF BD

    • Officer
    • Director
    		 162,495 2007-04-16 0

    GOLDMAN ALFRED E SUBSIDIARY OFFICER

    • Officer
    		 52,547 2007-04-16 0

    GALLI CHARLES J SUBSIDIARY OFFICER

    • Officer
    		 102,909 2007-04-16 0

    GRABISH RICHARD F SUBSIDIARY OFFICER

    • Officer
    		 68,441 2007-04-16 0

    KELLY DOUGLAS L CFO & CORP. SECRETARY

    • Officer
    		 81,814 2007-04-16 0

    KESSLER RONALD J VICE CHAIRMAN

    • Officer
    		 157,140 2007-04-16 0

    MILLER PETER M EXECUTIVE VP

    • Officer
    		 72,349 2007-04-16 0

    PAUTLER PAUL F SUBSIDIARY OFFICER

    • Officer
    		 89,452 2007-04-16 0

    PORTER JOSEPH G ASST CORP SECRETARY

    • Officer
    		 18,712 2007-04-16 0

    ATKIN MARY VERANTH SUBSIDIARY OFFICER

    • Officer
    		 68,959 2007-04-16 0

    PARKER JOHN CHARLES II SUBSIDIARY OFFICER

    • Officer
    		 36,701 2007-04-16 0

    DIEDERICH GENE M EXECUTIVE VP

    • Officer
    		 43,804 2007-04-16 0

    ESCARRA VICKI B

    • Director
    		 5,173 2006-12-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AGEX THERAPEUTICS INC AGE 2023-10-02 22:15:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 21:45:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 21:15:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 20:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 20:15:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 19:45:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 19:15:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 18:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 18:15:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 17:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 17:15:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 16:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 16:15:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 15:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 15:15:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 14:45:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 14:15:03 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 13:45:04 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 13:15:05 UTC -4.0947 9.4147 400000
    AGEX THERAPEUTICS INC AGE 2023-10-02 12:45:05 UTC -4.0947 9.4147 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AGE -1000.0 shares, $-893.2 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments